Pudong, Shanghai Office

510-947-7918

Washington Office

510-947-7918
Claire Sun
Senior Partner
Claire Sun

Claire Sun is Senior Partner at IPO Pang and her practice includes foreign direct investment, market entry, Sino-foreign joint ventures, cross-border mergers and acquisitions, corporate transactions and civil and commercial dispute resolution.

Ms. Sun graduated from the University of Hertfordshire School of Law (UK) with an LLB (Honours) degree and interned at Allen & Overy (London). With a deep understanding of the Anglo-American legal system and Western culture, she has been practicing law in Shanghai for fifteen years, consistently helping clients achieve recognized results.

Ms. Sun excels at assessing market trends, regulatory environments, and client needs to provide comprehensive and viable solutions. She specializes in leading complex projects involving foreign direct investment including China site setup, brand market entry, Sino-foreign joint ventures, corporate mergers and acquisitions (M&A), and the design of exit strategies. Additionally, she possesses extensive practical experience in civil and commercial dispute resolution in most contractual disputes and shareholder dispute, where her deep background in litigation provides a distinct advantage when handling commercial transactions.

Her areas of expertise include healthcare, biopharmaceutical, fintech, smart logistics, entermaintment and art. 

  • In 2018, she was selected as part of the first cohort by the Shanghai Bar Association for an international legal exchange training program in Washington, D.C.
  • In 2025, she was selected as an exchange lawyer for the Huangpu District foreign-related lawyer rule of law construction international arbitration program in Singapore.

Working Languages

  • Chinese 
  • English

Represented Cases (Selected):

Transaction:

  • A Certain Group: Equity investment transaction involving the Israeli company fetal heart monitoring — Project exited following IPO.
  • A Certain Group & Foreign Innovative Pharmaceutical Company: Joint R&D and licensing for a new gastric cancer treatment drug.
  • A Certain Group & US Company: R&D licensing and global commercialization rights transaction for a new drug. 
  • Biomedicine Company & Renowned International Medical Fund: Seed and several Series financing transaction.
  • Ping An Tsumura: Acquisition transaction involving Traditional Chinese Medicine (TCM) planting land and raw materials. 
  • Chemical Enterprise in Jiangsu & well-known French chemistry corporation: Foreign capital M&A transaction. 
  • ZACD Group (Singapore): Acquisition of domestic real estate transaction projects in China. 
  • UBox Technology (Singapore): Legal counsel for a smart logistics ecosystem project.
  • A Certain Group: Full-process legal services for introducing a Broadway musical performance project
  • Investment PE: Legal compliance for various projects in China. 
  • High-end European children’s brand : Exclusive general agency and distribution new retail project for a collective of high-end European children's brands. 
  • Sino-Foreign Cooperation/Joint Ventures: Strategic negotiation and documentation for the smooth exit of foreign investors.

Litigation/Arbitration:

  • Innovative Drug Licensing Agreement Dispute: Represented the client in a major breach of contract lawsuit. Won both the first and second instance trials, securing 3 million USD in liquidated damages and upholding the upfront payment.
  • Hong Kong Company Subsidiary Control Dispute: Represented a Hong Kong company in litigation regarding control rights over severval subsidiaries invested in China. Won both first and second instance trials (resulting in the replacement of senior management), laying the foundation for the client to take over the whole family business.
  • Singapore Foreign Investor Equity Transfer: Represented the client in an equity transfer (involving land and site buildings) successfully secured the transfer payment.
  • US Client Cross-Border Service Contract Arbitration: Represented a US client in an arbitration dispute at CIETAC (Beijing) successfully secured compensation.
Email IPO PANG